Anti-MMAE/MMAF monoclonal antibody(mAb)

Figure 2. The GTU-Bios-Auristatin-Ab-01-2 has been actively bound with the ADC (PTM-1 MMAF). While GTU-Bios-Auristatin-Ab-02-2 has not been bound with the ADC with MMAF.

In Figure 2, the specificity of GeneMedi's antibodies is showcased as GTU-Bios-Auristatin-Ab-01-2 successfully binds with the ADC (PTM-1 MMAF), while GTU-Bios-Auristatin-Ab-02-2 remains unbound. This specificity is pivotal in ensuring precise targeting of MMAE-containing ADCs, enhancing their therapeutic efficacy while minimizing off-target effects.

GeneMedi's ability to tailor antibodies to selectively bind with distinct drug payloads exemplifies their proficiency in antibody engineering, offering researchers reliable tools for precision medicine applications.

Figure 3. GTU-Bios-Auristatin-Ab-01-2 and GTU-Bios-Auristatin-Ab-02-2 have not been bound with the ADC conjugated with DXD.

Figure 3 illustrates another aspect of GeneMedi's antibody specificity, revealing that neither GTU-Bios-Auristatin-Ab-01-2 nor GTU-Bios-Auristatin-Ab-02-2 binds with the ADC conjugated with DXD. This data underscores GeneMedi's dedication to producing antibodies with high selectivity, ensuring minimal interference with undesired payloads.

By providing antibodies that exhibit minimal cross-reactivity, GeneMedi empowers researchers with precise tools for designing and optimizing ADCs for targeted cancer therapy, ultimately advancing the forefront of biomedical research and clinical applications.